Journal of Clinical Oncology, Vol 18, No 21S (November 1 Supplement)
2000: 47s-53s
© 2000 American Society for Clinical Oncology
Enhanced Apoptosis With Combination C225/Radiation Treatment Serves as the Impetus for Clinical Investigation in Head and Neck Cancers
By James A. Bonner,
Kevin P. Raisch,
Hoa Q. Trummell,
Francisco Robert,
Ruby F. Meredith,
Sharon A. Spencer,
Donald J. Buchsbaum,
Mansoor N. Saleh,
Murray A. Stackhouse,
Albert F. LoBuglio,
Glenn E. Peters,
William R. Carroll,
Harlan W. Waksal
From the University of Alabama at Birmingham, Comprehensive Cancer Center (Experimental Therapeutics Program), Birmingham, AL, and ImClone Systems, Inc, Somerville, NJ.
Address reprint requests to James A. Bonner, MD, Department of Radiation Oncology, University of Alabama at Birmingham, 1530 3rd Ave South, WTI 105, Birmingham, AL 35294-3300.
PURPOSE: Epidermal growth factor receptor (EGFr) is overexpressed in a majority of head and neck squamous cell carcinomas, and this overexpression is associated with a poor prognosis. Therefore, EGFr has become the target of investigations aimed at disabling the receptor to determine whether this process leads to improved tumor kill with conventional treatment.
MATERIALS AND METHODS: C225 is an anti-EGFr monoclonal antibody that inhibits receptor activity by blocking the ligand binding site. A panel of human head and neck squamous cell carcinoma cell lines was used to study the combination of C225 and radiation.
RESULTS: It was determined that the combination of C225 (5 µg/mL) delivered simultaneously with radiation (3 Gy) resulted in a greater decrement in cellular proliferation than either treatment alone. This reduction in proliferation correlated with reduced EGFr tyrosine phosphorylation and a reduction in phosphorylated signal transducer and activator of transcription-3 (STAT-3) protein (known to protect cells from apoptosis). Also, the decrement in proliferation correlated with increased apoptotic events, thereby indirectly linking C225/radiationinduced regulation of STAT-3 protein to apoptosis.
CONCLUSION: This preclinical work serves as important support for the ongoing clinical investigation of C225 and radiotherapy for patients with head and neck carcinomas. The initial results of these clinical studies have been promising.
J.A.B. receives financial reimbursement as a consultant to Imclone Systems, Inc.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. K. Ang
Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes
Oncologist,
August 1, 2008;
13(8):
899 - 910.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Worsham, K. M. Chen, N. Tiwari, G. Pals, J. P. Schouten, S. Sethi, and M. S. Benninger
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg,
April 1, 2006;
132(4):
409 - 415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. R. Schechter, R. E. Wendt III, D. J. Yang, A. Azhdarinia, W. D. Erwin, A. M. Stachowiak, L. D. Broemeling, E. E. Kim, J. D. Cox, D. A. Podoloff, et al.
Radiation Dosimetry of 99mTc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck
J. Nucl. Med.,
October 1, 2004;
45(10):
1683 - 1687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chakravarti, A. Chakladar, M. A. Delaney, D. E. Latham, and J. S. Loeffler
The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner
Cancer Res.,
August 1, 2002;
62(15):
4307 - 4315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chakravarti, J. S. Loeffler, and N. J. Dyson
Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinositide 3-Kinase Signaling
Cancer Res.,
January 1, 2002;
62(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|